




PHARMACEUTICAL 2022

Schrodinger Inc.
Rank 173 of 466





RealRate

PHARMACEUTICAL 2022

Schrodinger Inc.
Rank 173 of 466



The relative strengths and weaknesses of Schrodinger Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Schrodinger Inc. compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 36% points. The greatest weakness of Schrodinger Inc. is the variable Liabilities, Non-Current, reducing the Economic Capital Ratio by 17% points.

The company's Economic Capital Ratio, given in the ranking table, is 179%, being 101% points above the market average of 78%.

Input Variable	Value in 1000 USD
Assets, Current	625,060
Cost of Goods Sold	72,311
Intangible Assets	0
Liabilities, Current	91,211
Liabilities, Non-Current	78,127
Other Assets	121,402
Other Compr. Net Income	-142
Other Expenses	22,561
Other Liabilities	30,064
Other Net Income	10,635
Other Revenues	137,931
Property and Equipment	10,025
Research and Development	90,904
Selling, General and Administrative Expense	64,009

Output Variable	Value in 1000 USD
Assets	756,487
Liabilities	199,402
Expenses	249,785
Revenues	137,931
Stockholders Equity	557,085
Net Income	-101,219
Comprehensive Net Income	-101,290
Economic Capital Ratio	179%